Information on the target
ALPHA TALENTS AFRICA, led by Founder and Manager Roland Decorvet, has officially acquired a majority stake in PHARMAKINA, a company based in Bukavu, South Kivu. PHARMAKINA specializes in the processing of cinchona, a plant known for its medicinal properties, particularly in the production of quinine, a long-established treatment for malaria. With this acquisition, Decorvet now chairs the board of directors of PHARMAKINA, signaling a strategic move to enhance local production capabilities.
In his meeting with the Congolese government, Decorvet emphasized the company's commitment to investing not only in the acquisition of PHARMAKINA but also in the development of the cinchona processing plant and the cultivation of this vital plant by small farmers in North and South Kivu. His vision reflects a strong belief in the potential of the Democratic Republic of Congo (DRC) as a hub for quinine production.
Industry overview in the target’s specific country
The Democratic Republic of Congo is home to approximately 80% of the world's cinchona cultivation, yet only 20% of this resource is processed locally by PHARMAKINA. The remaining 80% is exported in its raw form, primarily to India, where it is transformed and then sold back to the DRC at significantly inflated prices. This situation highlights a critical gap in the local pharmaceutical industry, which could benefit from increased investment and infrastructure development.
Despite the DRC's rich natural resources, the local pharmaceutical sector has faced numerous challenges, including inadequate industrialization and regulatory frameworks. The reliance on foreign processing not only diminishes local economic opportunities but also contributes to the high costs of essential medications for the Congolese population. There is a pressing need for the government to implement policies that encourage local processing and reduce the export of raw materials.
Roland Decorvet's initiative to invest in PHARMAKINA represents a pivotal step towards addressing these challenges. By focusing on local production and processing, the company aims to create a sustainable supply chain that benefits both the economy and the health of the population. The potential for growth in the pharmaceutical industry in the DRC is substantial, provided that local resources are utilized effectively and investments are made in infrastructure and technology.
The rationale behind the deal The acquisition of PHARMAKINA by ALPHA TALENTS AFRICA is driven by a strategic vision to capitalize on the DRC's abundant cinchona resources while addressing the critical need for local processing cap…